City Therapeutics Launches with $135M to Advance RNAi-Based Medicines
• City Therapeutics launched with $135 million in Series A funding to innovate RNA interference (RNAi) therapeutics, led by Alnylam's former CEO, John Maraganore.
• The company aims to develop smaller, more potent RNAi triggers and enhance delivery to various tissues beyond the liver, expanding therapeutic applications.
• City Therapeutics plans to advance one to two new drugs into clinical trials each year, starting around the end of 2025, targeting multiple disease indications.
• The startup's siRNA-engineering platform focuses on designing and optimizing RNAi-based medicines with improved potency, specificity, and delivery methods.
© Copyright 2025. All Rights Reserved by MedPath